FSCN1 and cancer: Although in vitro studies using FSCN1-specific nanobodies in breast (MDA-MB-231) and prostate (PC3) cancer cells inhibited the formation of invadopodium and cell invasion [187], the use of FSCN1-specific antibodies in clinical settings needs to be established.